This inventor holds 4 USPTO granted patents and 9 published patent applications. Top assignees: Cdr-Life Ag, Boehringer Ingelheim International Gmbh. Active years: 2024-2025.
Company Filing History:
4 out of 4 
1 out of 1,560 
Years Active: 2024-2025
Title: Fabian Bert Scheifele: Innovator in Antigen Binding Proteins
Introduction
Fabian Bert Scheifele is a notable inventor based in Mägenwil-Aargau, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. With a total of four patents to his name, Scheifele's work has the potential to impact various medical applications.
Latest Patents
Among his latest patents is the invention of rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same. This patent provides nucleic acid libraries encoding antigen binding proteins that specifically recognize target peptide-MHC (pMHC). Additionally, he has developed anti-C3 antibodies and antigen-binding fragments, which are aimed at treating eye or ocular diseases. This invention focuses on antibodies that target complement C3, offering methods for treating various diseases or disorders.
Career Highlights
Scheifele has worked with prominent companies in the biotechnology sector, including Cdr-Life AG and Boehringer Ingelheim International GmbH. His experience in these organizations has contributed to his expertise in the development of innovative medical solutions.
Collaborations
Throughout his career, Scheifele has collaborated with talented individuals such as Anna Maria Sobieraj and Stephanie Jungmichel. These partnerships have likely enhanced his research and development efforts.
Conclusion
Fabian Bert Scheifele is a distinguished inventor whose work in antigen binding proteins and related technologies holds promise for advancements in medical treatments. His contributions to the field are noteworthy and reflect his commitment to innovation.